Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ADDXFOTCMKTS:AFFYOTCMKTS:AOLSOTCMKTS:BAYRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADDXFAddex Therapeutics$0.99$0.99$0.99▼$0.99N/A0.25N/AN/AAFFYAffymax$0.00$0.00$0.00▼$0.00N/A7.342,186 shs35,050 shsAOLSAeolus Pharmaceuticals$0.00$0.00▼$0.01N/A1.2835 shs35 shsBAYRYBayer Aktiengesellschaft$7.67-1.4%$7.18$4.79▼$8.58$30.57B0.86540,619 shs369,176 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADDXFAddex Therapeutics0.00%0.00%0.00%0.00%0.00%AFFYAffymax0.00%0.00%+700.00%-66.67%-61.90%AOLSAeolus Pharmaceuticals0.00%0.00%0.00%0.00%0.00%BAYRYBayer Aktiengesellschaft-1.41%0.00%+7.72%+39.45%+8.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ABAYRYBayer AktiengesellschaftN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADDXFAddex Therapeutics 0.00N/AN/AN/AAFFYAffymax 0.00N/AN/AN/AAOLSAeolus Pharmaceuticals 0.00N/AN/AN/ABAYRYBayer Aktiengesellschaft 3.25BuyN/AN/ACurrent Analyst Ratings BreakdownLatest BAYRY, ADDXF, AOLS, and AFFY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025BAYRYBayer AktiengesellschaftHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/11/2025BAYRYBayer AktiengesellschaftKepler Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy6/5/2025BAYRYBayer AktiengesellschaftThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/28/2025BAYRYBayer AktiengesellschaftHsbc Global ResSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADDXFAddex TherapeuticsN/AN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/AN/ABAYRYBayer Aktiengesellschaft$50.44B0.60$3.74 per share2.05$8.82 per share0.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADDXFAddex TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AAFFYAffymaxN/AN/A0.00∞N/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/ABAYRYBayer Aktiengesellschaft-$2.76B-$0.92N/A6.73N/A-7.26%13.94%4.09%8/5/2025 (Estimated)Latest BAYRY, ADDXF, AOLS, and AFFY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BAYRYBayer Aktiengesellschaft$0.63$0.65+$0.02$0.35$13.39 billion$15.27 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADDXFAddex TherapeuticsN/AN/AN/AN/AN/AAFFYAffymaxN/AN/AN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/AN/AN/ABAYRYBayer Aktiengesellschaft$0.020.26%N/AN/A N/ALatest BAYRY, ADDXF, AOLS, and AFFY DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/22/2025BAYRYBayer Aktiengesellschaft$0.02240.38%4/29/20254/30/20255/12/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADDXFAddex TherapeuticsN/AN/AN/AAFFYAffymaxN/AN/AN/AAOLSAeolus PharmaceuticalsN/AN/AN/ABAYRYBayer Aktiengesellschaft1.071.250.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADDXFAddex TherapeuticsN/AAFFYAffymaxN/AAOLSAeolus PharmaceuticalsN/ABAYRYBayer AktiengesellschaftN/AInsider OwnershipCompanyInsider OwnershipADDXFAddex TherapeuticsN/AAFFYAffymax1.55%AOLSAeolus Pharmaceuticals66.60%BAYRYBayer AktiengesellschaftN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADDXFAddex Therapeutics26N/AN/ANot OptionableAFFYAffymax4N/AN/ANot OptionableAOLSAeolus Pharmaceuticals4N/AN/ANot OptionableBAYRYBayer Aktiengesellschaft92,8153.93 billionN/ANot OptionableBAYRY, ADDXF, AOLS, and AFFY HeadlinesRecent News About These CompaniesOfficial | Bayer Leverkusen talent Kerim Alajbegovic joins RB Salzburg | OneFootball2 hours ago | onefootball.comOFrom Bayer Leverkusen to FC Red Bull Salzburg2 hours ago | sports.yahoo.comBayer Leverkusen could pursue Monaco’s Maghnes Akliouche this summer if no other clubs do2 hours ago | sports.yahoo.comBayer Leverkusen sporting director Rolfes: How Liverpool won Wirtz battle2 hours ago | tribalfootball.comTBayer’s Promising Parkinson’s Study: AAV2-GDNF Gene Therapy in FocusJuly 3 at 1:14 PM | tipranks.comWhat Makes Bayer (BAYRY) a New Buy StockJuly 3 at 1:00 PM | zacks.comErik ten Hag risks wrath of Bayer Leverkusen fans with message to Jarell QuansahJuly 2 at 1:50 PM | mirror.co.ukMBayer 04 first team and youth players start preseason on 7 JulyJuly 2 at 1:50 PM | bayer04.deBBayer Leverkusen chief reveals new transfer strategyJuly 2 at 1:50 PM | tribalfootball.comTBayer Leverkusen Transfers: Jarell Quansah Completes Move From Liverpool For £35mJuly 2 at 1:50 PM | outlookindia.comBayer Leverkusen complete signing of Liverpool defender Jarell QuansahJuly 2 at 8:50 AM | nytimes.comPSV in discussions to sign Bayer Leverkusen’s Matěj Kovář | OneFootballJuly 2 at 8:50 AM | onefootball.comODONE DEAL: Bayer Leverkusen close signing of Liverpool defender QuansahJuly 2 at 8:50 AM | tribalfootball.comTU21 Euros winner Jarell Quansah joins Bayer 04 from LiverpoolJuly 2 at 8:50 AM | bayer04.deBBayer Leverkusen sign Liverpool defender Jarell QuansahJuly 2 at 8:50 AM | modernghana.comMBayer Leverkusen confirm record signing of Jarell Quansah from Liverpool | OneFootballJuly 2 at 8:50 AM | onefootball.comOBayer Leverkusen’s Simon Rolfes: “Our goal is to use the transfer fee for Florian to build the next title-winning team”July 2 at 8:50 AM | sports.yahoo.comLiverpool defender Quansah signs for Bayer LeverkusenJuly 2 at 8:50 AM | msn.comLongtime Bayer executive takes helm of North American finance operationsJuly 1 at 2:55 PM | bizjournals.comBAYRY - Bayer AG ADR Price vs Fair Value | MorningstarJuly 1 at 2:55 PM | morningstar.comMBayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Down 4.1% - Here's What HappenedJune 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBAYRY, ADDXF, AOLS, and AFFY Company DescriptionsAddex Therapeutics OTCMKTS:ADDXF$0.99 0.00 (0.00%) As of 02/3/2023Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Affymax OTCMKTS:AFFY$0.0008 0.00 (0.00%) As of 06/27/2025Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.Aeolus Pharmaceuticals OTCMKTS:AOLSAeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious, and central nervous system diseases in the United States. The company develops a class of catalytic antioxidant compounds as medical countermeasures against nuclear, radiological, and chemical weapons, as well as for diseases and disorders of the respiratory system, central nervous system, and oncology. Its lead compound includes AEOL 10150 that has completed two Phase I clinical trials, which is developed against the pulmonary sub-syndrome of acute radiation syndrome; and for use as a medical countermeasure for exposure to chemical vesicants and nerve agents. The company is also developing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, as well as AEOL 20415 for treating infectious diseases. Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California.Bayer Aktiengesellschaft OTCMKTS:BAYRY$7.67 -0.11 (-1.41%) As of 07/3/2025 12:58 PM EasternBayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines for self-medication and self-care; and solutions for nutritional supplements, allergy, cough and cold, dermatology, pain and cardiovascular risk prevention, and digestive health. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration with Acuitas Therapeutics, Inc. to strengthen gene editing programs; Peking University in the area of basic pharmaceutical research; the Swiss Tropical and Public Health Institute in the development of the compound emodepside for the treatment of infection with soil-transmitted helminths; bit.bio Ltd. for the discovery and manufacture of regulatory T cells for use in creating therapeutics; Hologic, Inc. in the field of contrastenhanced-mammography solutions to improve diagnostic imaging for the detection of breast cancer; and Twist Bioscience Corporation centering around the research and development of antibody-based pharmaceuticals, as well as with CrossBay Medical Inc. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company has collaboration with Thermo Fisher Scientific. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
